"The committee has established a set of metrics that considers, among other things, whether the program has optimal faculty-to-fellow ratios for learning, appropriately credentialed faculty, and a balance between broad-based clinical training, mentorship, and research training," says Dr. Babb. "We view this as essential to ensuring that the next generation of interventionalists is prepared to deliver the best possible care to future patients."
Although Boston Scientific and Cordis Corporation have supported fellow training for years, the SCAI Interventional Cardiology Fellows-in-Training Grant Program represents a new approach to both companies' investment in medical education. Both companies will support interventional cardiology fellowship grants through the new SCAI program.
"Boston Scientific is pleased to be able to advance medical education in this critical field. We believe that SCAI's program will ultimately produce a cadre of highly trained interventionalists prepared to be leaders in patient care and research innovation," says Donald S. Baim, M.D., Executive Vice President, Chief Medical and Scientific Officer at Boston Scientific Corporation.
Cordis agrees. According to David Kandzari, M.D., FACC, FSCAI, Chief
Medical Officer, Cordis Corporation, "Support for education and training of
our next generation of interventional cardiologists has been a
long-standing commitment for Cordis. We are especially pleased that the
Cordis Cardiac and Vascular Institute has an opportunity to invest in this
program led by SCAI. We believe that a medical society, l
|SOURCE Society for Cardiovascular Angiography and Interventions|
Copyright©2007 PR Newswire.
All rights reserved